Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Assets (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Assets data on record, last reported at $529.7 million in Q4 2025.

  • For Q4 2025, Assets fell 26.92% year-over-year to $529.7 million; the TTM value through Dec 2025 reached $529.7 million, down 26.92%, while the annual FY2025 figure was $529.7 million, 26.92% down from the prior year.
  • Assets reached $529.7 million in Q4 2025 per SNDX's latest filing, down from $551.8 million in the prior quarter.
  • Across five years, Assets topped out at $724.8 million in Q4 2024 and bottomed at $239.5 million in Q3 2021.
  • Average Assets over 5 years is $465.5 million, with a median of $454.7 million recorded in 2021.
  • Peak YoY movement for Assets: skyrocketed 165.96% in 2021, then decreased 26.92% in 2025.
  • A 5-year view of Assets shows it stood at $449.7 million in 2021, then grew by 10.58% to $497.2 million in 2022, then rose by 23.26% to $612.9 million in 2023, then grew by 18.26% to $724.8 million in 2024, then fell by 26.92% to $529.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $529.7 million in Q4 2025, $551.8 million in Q3 2025, and $596.1 million in Q2 2025.